



PRODUCT ENQUIRY / LEAFLET FOR DOG / PET OWNERS

To obtain CV247, please telephone CV Pharma's Distributor on 0808 156 1686 or +44 (0) 1527 505 470; Fax: +44 (0)1572 505 482 or email sales@chemist.net, with a copy of your Prescription. If you do not have a valid Prescription please refer to the list of prescribing Vets on our Website www.cv-pharma.com

CV247 is only available as an Authorised Product for dogs under our Hungarian Licence no 253/1/2011 MgSzH ATI as a veterinary paramedicinal product.

What you should know about CV247.

CV247 can only be prescribed for an animal by a Veterinarian. It should not be passed on to others.

CV247 is patented by Ivy Medical Chemicals Development Limited, a wholly-owned subsidiary of CV Pharma Ltd, under Patent Number GB2374008B.

What is CV247?

CV247 is a palliative treatment for cancer that is formulated to treat cancer sufferers as a result of their deficiency of certain naturally occurring substances in the body. By replacing these substances, CVTherapy may bring about an improvement in the quality of life and potentially prevent the reoccurrence of tumours, and has no known serious or severe adverse side effects.

Benefits of CV247.

- Strengthens the immune system which provides improved Quality of Life
- Forms part of the body's anti-oxidant defences
- May prevent the reoccurrence of tumours
- May aid recovery from surgery, chemotherapy or radiotherapy
- May be taken adjunctively with chemotherapy and radiotherapy

Before you use CV247.

CV247 has been available for a significant number of years, and has proved to have minimal adverse side effects. However, like all medicines, CV247 could potentially have minor side effects. Experiences from studies have demonstrated that adverse side effects are occasionally reported, predominantly relating to mild gastro-intestinal events such as gastric irritation, abdominal pain and bloating. No serious or severe reactions have ever been reported.

CV247 Clinical Trials.

CV247 has been the subject of a number of pre-clinical studies undertaken to ascertain the anti-tumour properties of CV247 in animals and humans:

- A study in mice undertaken by Prof P Beverley at the Middlesex Hospital demonstrated a measurable reduction in the rate of tumour growth
- A study undertaken in mice by Biodynamics Ltd, which demonstrated tumour reduction was more apparent following treatment using CVTherapy rather than alternative substances.
- A chronic toxicology study was undertaken at Huntingdon Life Sciences, providing evidence that CVTherapy in dogs has a very low side effect profile, with no reports of either severe or serious adverse effects attributable to the drug.
- A study undertaken by Prof R Thomas at Addenbrooke's and Bedford Hospital evaluated the tumour static properties of CVTherapy, which wholly supported the clinical benefit in some types of cancer.
- A second study by Prof R Thomas, which resulted in a significant percentage of prostate cancer patients, who were recruited into the study, being stabilised following the treatment.
- A study undertaken by Dr Ros Taylor of the St Francis Hospice in Berkhamstead in order to ascertain how CVTherapy influenced quality of life found positive results in some patients with late stage cancers.
- A retrospective assessment conducted by Dr Ros Taylor over 5 years demonstrated significant symptom improvement or disease stabilisation in many patients.
- A preliminary viability investigation study undertaken by RGCC Limited (Research Genetic Cancer Centre) found that, after CVTherapy was added to a range of human cancer cell lines, it had a direct anti-cancer activity particularly in breast and colon cancers.
- A study in rats undertaken at Semmelweis University in Budapest found that CVTherapy reduced the oxidative effects and reversed the cisplatin induced renal damage.

How to use CV247.

CV247 should only be taken as prescribed. CV247 is supplied in blister packs in cardboard cartons. CV247 is a combination product with each unit consisting of 30 sodium salicylate 175mg tablets and 30 Essential Minerals and Vitamin C capsules (each capsule contains copper gluconate 10mg; manganese gluconate 10mg and ascorbic acid (Vitamin C) 200mg).

When the animal responds to treatment, the frequency and dose of administration may be reduced or modified on the advice of the treating veterinary surgeon who should periodically assess progress. For the prevention of tumour recurrence a lower dosage may be sufficient.

Dosage.

Dosing recommendations are based upon weight, and the risk of repeated overdosing is considered to be unlikely. There are no documented symptoms associated with an overdose.

The dose is one Essential Minerals/Vitamin C capsule and one tablet of Sodium Salicylate per day for a dog of 10 Kg bodyweight, according to the following Table:

Bodyweight	CV247 daily dosage
<5Kg	half capsule and half tablet once a day
5-15 Kg	one capsule and one tablet once a day
15-25 Kg	one capsule and one tablet twice a day
25-40 Kg	one capsule and one tablet three times a day
>40 Kg	two capsules and two tablets twice a day

Units may be applied with food once or twice per day.

Administration of the Capsule and Tablet

a. Either if the owner is experienced enough and the dog is placid enough, put them one by one onto the base of the tongue and then hold the mouth closed by hand for a while, until the dog swallows them. For dogs with good appetite they can be offered hidden